Gastroesophageal Junction Adenocarcinoma

Oncology
3
Pipeline Programs
3
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Docetaxel, Leucovorin, Fluorouracil, CisplatinPhase 2
Genentech
GenentechCA - Oceanside
1 program
1
Docetaxel, Leucovorin, Fluorouracil, CisplatinPhase 2
Ipsen
IpsenChina - Tianjin
1 program
1
FOLFOX/ nal-IRIPhase 21 trial
Active Trials
NCT04656041Recruiting40Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IpsenFOLFOX/ nal-IRI

Clinical Trials (1)

Total enrollment: 40 patients across 1 trials

NCT04656041IpsenFOLFOX/ nal-IRI

Folfox+Irinotecan+Chemort In Esophageal Cancer

Start: Jun 2021Est. completion: Dec 202740 patients
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 40 patients
3 companies competing in this space